F S&P 500
5,357.25 +29.25 (+0.55%) F Dow Jones
39,827.00 +44.00 (+0.11%) F Nasdaq
18,950.00 +163.25 (+0.87%) E-mini Russell 2000 Index Futur
2,095.30 +6.20 (+0.30%) Petróleo
77.01 -0.56 (-0.72%) Oro
2,372.30 -20.60 (-0.86%)
Senzime AB (publ) (SNZZF)
Senzime AB (publ)
Ulls väg 41
Uppsala 756 51
Sweden
46 18 51 56 40
https://www.senzime.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 52
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Philip Siberg | Chief Executive Officer | 4.6M | N/D | 1973 |
| Mr. Slavoljub Grujicic | Chief Financial Officer | N/D | N/D | 1970 |
| Ms. Johanna Tulkki | Chief Operating Officer | N/D | N/D | 1970 |
| Mr. Fredrik Norrby | Chief Technology Officer | N/D | N/D | 1976 |
| Ms. Rianne Lundqvist Waninge Ph.D. | Application Scientist | N/D | N/D | N/D |
| Ms. Paula Treutiger | Head of Communication & Investor Relations | N/D | N/D | 1967 |
| Mr. Anders Selin | Executive Vice President of Sales | N/D | N/D | 1962 |
| Michael Noble | Vice President Global Marketing | N/D | N/D | 1988 |
| Mr. Anders Jacobson | Chief Innovation Officer | N/D | N/D | 1967 |
| Ms. Catrin Molund | Executive Vice President of Business Development | 163k | N/D | 1970 |
Descripción
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue's opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Senzime AB (publ) a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
